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Despite recent restrictions on further pro-
duction for home use, chlorpyrifos remains
the most widely used organophosphate pesti-
cide, and there is increasing concern over the
potential consequences of fetal and child-
hood exposures (1). The acute toxicity of
chlorpyrifos is mediated through inhibition
of cholinesterase by the active metabolite
chlorpyrifos oxon, but new evidence suggests
that chlorpyrifos itself may influence brain
cell replication and differentiation directly
(1–11). Indeed, the greater toxicity of chlor-
pyrifos in juvenile animals cannot be explained
solely by developmental differences in activi-
ties directed toward cholinesterase or neuro-
toxic esterase, nor do age-related increments in
chlorpyrifos metabolism account for differen-
tial toxicity (12); immature animals actually
recover more rapidly from cholinesterase inhi-
bition, so measurements of cholinesterase
activity other than in the immediate exposure
period can give a misleading assessment of
adverse effects (7,13–15).
Attempts have been made to model the
mechanisms underlying the developmental
neurotoxicity of chlorpyrifos in vitro, using
either transformed neural cell lines
(1,6,11,16–18) or cultures of immature brain
tissue (10,19,20). Although transformed cells,
such as the neuronotypic PC12 cell line, are
typically less responsive to neurotoxins such as
chlorpyrifos, they have proven especially use-
ful in establishing cell replication as a major
target because they maintain a ﬁxed pattern of
mitosis until differentiation is triggered by
addition of trophic factors and deletion of
serum (1,6,8,17,18,21–23). We recently
found that replication of C6 cells, a gliotypic
line, is also affected by chlorpyrifos (18);
because glial development continues well into
the postnatal period, this would in turn imply
that the sensitive window for developmental
neurotoxicity of chlorpyrifos could extend
into childhood or even early adolescence.
The current work addresses several unan-
swered questions about the effects of chlor-
pyrifos on PC12 and C6 cells. First, to what
extent does the antimitotic effect of chlor-
pyrifos extend to its major metabolites,
chlorpyrifos oxon, the active inhibitor of
cholinesterase, or trichloropyridinol, the
catabolic product that is prominent in fetal
brain after maternal chlorpyrifos exposure
(24), which has been identiﬁed almost ubiq-
uitously in urine samples of U.S. school chil-
dren (25,26)? Second, are the effects of
chlorpyrifos unique, or are they shared by
other organophosphates such as diazinon, or
by non-organophosphate cholinesterase
inhibitors? Diazinon, like chlorpyrifos, has
recently undergone major changes in its
approved uses, with an initial phasing out of
indoor use to be followed by reduced agricul-
tural use (25–27). Third, to what extent
might serum proteins protect the developing
brain from the adverse effects of chlorpyrifos?
It has recently been suggested that catabolic
enzymes present in the serum could inﬂuence
the neurotoxic effects of chlorpyrifos, at least
in vitro (11,18,28), and other organophos-
phates show signiﬁcant binding to plasma pro-
teins (29). Fourth, to what extent might glia
be affected preferentially to neurons? The stan-
dard growth conditions for these cell lines
entail the addition of different sera and their
associated proteins, so it is difﬁcult to compare
the actual vulnerability of gliotypic and neu-
ronotypic cell lines (1,18). We have therefore
compared the effects of chlorpyrifos as well as
the other agents on gliotypic C6 and neurono-
typic PC12 cells in experiments matching the
incubation conditions so as to obviate any dif-
ferential effects of serum proteins.
Materials and Methods
PC12 cells (American Type Culture
Collection, CRL 1721; Duke University
Comprehensive Cancer Center, Durham,
NC) were seeded onto 60-mm poly-L-lysine-
coated plates and grown for 48 hr at 37°C in
7.5% CO2, using RPMI-1640 medium sup-
plemented with 10% heat-inactivated horse
serum, 5% inactivated fetal bovine serum,
and 25 µg/mL penicillin–streptomycin (all
from Gibco, Grand Island, NY). C6 cells
(American Type Culture Collection, CCL
107) were maintained in Dulbecco’s
Modified Eagle’s Medium supplemented
with 5% inactivated fetal bovine serum and
100 µg/mL penicillin–streptomycin. We
conducted experiments toward the end of
log-phase growth, when the cells had
achieved about 70% conﬂuence (1,18).
To initiate the measurement of DNA
synthesis, we aspirated the medium and
replaced it with medium containing 1
µCi/mL of [3H]thymidine (speciﬁc activity,
2 Ci/mmol; New England Nuclear Corp.,
Boston, MA), adding various concentrations
of chlorpyrifos (Chem Service, West
Chester, PA), chlorpyrifos oxon [U.S.
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The widely used organophosphate pesticide chlorpyrifos is a suspected neuroteratogen. In the
current study, we compared the effects of chlorpyrifos and its major metabolites in two in vitro
models, neuronotypic PC12 cells and gliotypic C6 cells. Chlorpyrifos inhibited DNA synthesis in
both cell lines but had a greater effect on gliotypic cells. Chlorpyrifos oxon, the active metabolite
that inhibits cholinesterase, also decreased DNA synthesis in PC12 and C6 cells with a preferen-
tial effect on the latter. Trichloropyridinol, the major catabolic product of chlorpyrifos, had a
much smaller, but nevertheless statistically signiﬁcant, effect that was equivalent in both cell lines.
Diazinon, another organophosphate pesticide, also inhibited DNA synthesis with preference
toward C6 cells, but was less effective than was chlorpyrifos. Physostigmine, a non-organophos-
phate cholinesterase inhibitor, was less effective than either chlorpyrifos or diazinon, but still
caused significant inhibition of DNA synthesis in C6 cells. We also found that the addition of
sera protected the cells from the adverse effects of chlorpyrifos and that the effect could be repro-
duced by addition of albumin. These results indicate that chlorpyrifos and other organophos-
phates such as diazinon have immediate, direct effects on neural cell replication, preferentially for
gliotypic cells. In light of the protective effect of serum proteins, the fact that the fetus and new-
born possess lower concentrations of these proteins suggests that greater neurotoxic effects may
occur at blood levels of chlorpyrifos that are nontoxic to adults. Key words: C6 cells, chlorpyrifos,
developmental neurotoxicity, diazinon, DNA synthesis, PC12 cells, physostigmine. Environ
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EPA), Research Triangle Park, NC], 3,5,6-
trichloropyridinol (TCP; U.S. EPA), diazi-
non (Chem Service) or physostigmine
(Sigma Chemical Co., St. Louis, MO). We
dissolved the drugs in DMSO (Sigma) to
produce a final DMSO concentration of
0.1% in the culture medium, and treated the
control cultures with the vehicle; preliminary
experiments verified the lack of effect of
0.1% DMSO. Depending on the specific
experiment, the type of serum mixture and
total serum concentration was changed at
the same time as the radiolabel was added.
These conditions, as well as the concentra-
tions of test compounds, are described with
each experiment and are commensurate
with those used in earlier in vitro studies
(1,11,18,19,21–23,30–32). One hour after
adding [3H]thymidine, we aspirated the
medium and homogenized the cells in 3.5
mL of ice-cold water. Duplicate aliquots of
each sample were treated with 10%
trichloroacetic acid (TCA) and sedimented
at 1,000 g for 15 min to precipitate macro-
molecules. The resultant pellet was washed
once with TCA and then with 75% ethanol.
The ﬁnal pellet was then hydrolyzed in 1 M
KOH overnight at 37°C and neutralized
with 6 M HCl; the DNA was then precipi-
tated with ice-cold 5% TCA and sedimented
at 1,000 g for 15 min. The pellet from this
ﬁnal step was hydrolyzed in 5% TCA for 15
min at 90°C and resedimented, and an
aliquot of the supernatant solution was
counted for [3H]thymidine incorporation.
We assayed another aliquot for DNA spec-
trophotometrically by absorbance at 260
nm. Previous work has demonstrated quan-
titative recovery of macromolecules by these
techniques (33). We corrected incorporation
values for the total amount of DNA to pro-
vide an index of DNA synthesis per cell.
Data analysis. Data are presented as
means and standard errors, with differences
among groups established by analysis of vari-
ance (ANOVA) followed by Fisher’s protected
least signiﬁcant difference for individual com-
parisons. Signiﬁcance was assumed at p < 0.05.
To facilitate visual comparison across differ-
ent cell types and incubation conditions, we
present results as the percentage of the corre-
sponding DMSO control group; however,
statistical comparisons were based on the
original data (log transformed whenever the
variance was heterogeneous).
Results
In the first set of experiments, we exposed
PC12 and C6 cells to chlorpyrifos or chlor-
pyrifos metabolites for 1 hr in the absence of
serum, to obviate any potential protective
effect of serum proteins (11,18,28,29),
selecting a chlorpyrifos concentration (30
µM) previously found to cause robust but
submaximal inhibition of DNA synthesis in
vitro (1,18). Exposure of either cell type to
chlorpyrifos elicited an immediate decrement
in DNA synthesis, with a signiﬁcantly greater
effect on the gliotypic C6 cells than on neu-
ronotypic PC12 cells (Figure 1). Equimolar
concentrations of chlorpyrifos oxon also pro-
duced signiﬁcant inhibition of DNA synthe-
sis, again with C6 cells showing a greater
effect than PC12 cells; however, chlorpyrifos
oxon was also signiﬁcantly less effective than
was chlorpyrifos itself. At the same concen-
tration, TCP produced less inhibition than
chlorpyrifos or chlorpyrifos oxon but never-
theless still elicited a statistically significant
decrement in DNA synthesis; in contrast to
the effects of chlorpyrifos and chlorpyrifos
oxon, the small effect seen for TCP did not
display selectivity toward C6 cells. Given that
the cells were exposed for only 1 hr, it is not
surprising that there were no changes in total
cell number, as evaluated by DNA content
(data not shown); earlier work has demon-
strated a lack of effect on cell viability at this
chlorpyrifos concentration and duration of
exposure (1,18).
We next compared the effects of chlor-
pyrifos to those of other cholinesterase
inhibitors, again using equivalent concentra-
tions (30 µM) of each compound (Figure 2).
Both diazinon, an organophosphate, and
physostigmine, a competitive cholinesterase
inhibitor, caused significant inhibition of
DNA synthesis in C6 cells, with the rank
order chlorpyrifos > diazinon > physostig-
mine. For PC12 cells, diazinon caused a sig-
nificant decrement, albeit smaller than the
effect of chlorpyrifos, and physostigmine was
ineffective.
Until this point, studies were conducted
without the addition of sera to the incuba-
tion medium. Accordingly, we needed to
determine if inclusion of serum combina-
tions that are standard conditions for main-
taining PC12 and C6 cell growth could
influence the ability of chlorpyrifos to
inhibit DNA synthesis (Figure 3). For these
experiments, we reduced the chlorpyrifos
concentration to 15 µM to allow for more
sensitive detection of protective effects. At
this lower chlorpyrifos concentration, we
still observed robust inhibition of DNA syn-
thesis in the absence of serum, and again the
effect was greater in C6 cells. With addition
of 10% heat-inactivated horse serum and
5% heat-inactivated fetal bovine serum to
PC12 cells, the chlorpyrifos effect was sub-
stantially reduced but remained statistically
detectable. In contrast, adding just the 5%
heat-inactivated fetal bovine serum to C6
cells—the standard growth condition for this
cell line (18)—failed to provide any protec-
tion whatsoever. It is interesting that the addi-
tion of serum alone had a differential effect on
the two cell lines, with DNA synthesis
increasing in C6 cells and decreasing in PC12
cells (data in legend to Figure 3). This may
reﬂect differential effects of serum on cellular
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Figure 1. Effects of chlorpyrifos (CPF) and its
metabolites (30 µM) on DNA synthesis in PC12
and C6 cells. Data represent means and standard
errors obtained from 9–10 determinations for
each treatment and cell type, presented as the
percentage of corresponding control values:
17,400 ± 306 disintegrations per minute (dpm)/µg
DNA for PC12 cells; 7,500 ± 80 for C6 cells. DNA
content was 42 ± 4 µg/dish for PC12 cells and 29 ±
1 for C6 cells, and was unaffected by the treat-
ments (data not shown). ANOVA: treatment, p <
0.0001; treatment × cell type, p < 0.0001. Treatment
with chlorpyrifos, chlorpyrifos oxon, or TCP
elicited signiﬁcant reductions in DNA synthesis in
both cell types (a). For chlorpyrifos and chlorpyri-
fos oxon, the effects were signiﬁcantly greater in
C6 cells than in PC12 cells (b). The effect of chlor-
pyrifos oxon was signiﬁcantly smaller than that of
chlorpyrifos in either cell type (c), and the effect
of TCP was signiﬁcantly smaller than either of the
other two treatments (d). 
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Figure 2. Effects of cholinesterase inhibitors (30
µM) on DNA synthesis in PC12 and C6 cells. Data
represent means and standard errors obtained
from 10 determinations for each treatment and
cell type, presented as the percentage of corre-
sponding control values: 17,000 ± 600 dpm/µg
DNA for PC12 cells; 6,020 ± 240 for C6 cells. DNA
content was 31 ± 2 µg/dish for PC12 cells and 28 ±
1 for C6 cells, and was unaffected by the treat-
ments (data not shown). ANOVA: treatment, p <
0.0001; treatment × cell type, p < 0.0001. Treatment
with chlorpyrifos (CPF) or diazinon elicited signiﬁ-
cant reductions in DNA synthesis (a) in both cell
types, whereas physostigmine affected only C6
cells. For all three treatments, the effects were
signiﬁcantly greater in C6 cells than in PC12 cells
(b). The effect of diazinon was significantly
smaller than that of chlorpyrifos in either cell type
(c), and the effect of physostigmine was signifi-
cantly smaller than either of the other two treat-
ments (d).
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a,b,dmetabolism, because changes in serum condi-
tions can also elicit cell differentiation and/or
apoptosis in these cell lines (11,34–36).
It was not clear from these results alone
whether the lack of protective effect of
serum on C6 cells represented a different
underlying mechanism for chlorpyrifos
action compared to PC12 cells, whether the
key ingredient was the horse serum (which
was included for normal growth of PC12
cells but not C6 cells), or whether simply the
higher total serum protein concentration
from the combined sera represented the crit-
ical factor. Previous work had suggested that,
despite heat inactivation, horse serum retains
catabolic capabilities toward chlorpyrifos
oxon, and thus potentially toward chlorpyri-
fos (11). Accordingly, we performed further
studies with C6 cells, comparing different
serum mixtures (Figure 4). As before, 5%
fetal bovine serum had no signiﬁcant protec-
tive effect. However, addition of the PC12
serum mixture to C6 cells (10% horse serum
+ 5% fetal bovine serum) completely pro-
tected the C6 cells from the effects of chlor-
pyrifos. Surprisingly, a similar protective
effect could be obtained simply by adding
albumin in the same total protein concentra-
tion as the serum mixture.
Discussion
The current results are consistent with the
concept that chlorpyrifos exerts antimitotic
actions on developing neural cells indepen-
dently of cholinesterase inhibition (5,9,11).
First, we found that chlorpyrifos was more
effective than chlorpyrifos oxon, despite the
fact that the latter is a far more potent
cholinesterase inhibitor. Second, physostig-
mine, a non-organophosphate cholinesterase
inhibitor, was totally ineffective in inhibiting
DNA synthesis in PC12 cells and was less
effective than chlorpyrifos in C6 cells. These
results also agree with a recent study in which
chlorpyrifos, but not chlorpyrifos oxon or
physostigmine, disrupted maturation of sea
urchin embryos during the speciﬁc period in
which development is regulated by neu-
rotrophic factors (37). Although our studies
do not address the speciﬁc molecular or cellu-
lar mechanism by which chlorpyrifos disrupts
DNA synthesis, the rapidity of the effect,
with onset within as little as 1 hr, is consis-
tent with postulated actions at the level of
transcriptional events mediating cell division
and differentiation (6,8,18).
We found that gliotypic C6 cells are
much more sensitive than neuronotypic
PC12 cells. Although we had previously pos-
tulated preferential targeting of glia (18),
there were potential confounds in our com-
paring cultures with different combinations
of sera in the medium, and the current
results indicate that the greater sensitivity of
C6 cells is present even in the absence of
serum proteins. Adverse effects of chlorpyri-
fos on glial cell replication are of critical
importance in defining the sensitive period
for effects on central nervous system devel-
opment. Glia provide nutritional, structural,
and homeostatic support that are essential to
architectural modeling of the brain (38–42),
and because glial development continues
well into the postnatal period, glial targeting
implies a prolonged vulnerability, extending
into childhood. In keeping with this inter-
pretation, chlorpyrifos administration in
vivo inhibits DNA synthesis and causes loss
of brain cells during gliogenesis (2,4,43),
with maximal effects on neural function
appearing during peaks of glial development
(3,5,10,43,44). In aggregating brain-cell cul-
tures, chlorpyrifos affects glial markers, again
unrelated to cholinesterase inhibition (10).
The present results thus confirm conclu-
sively that chlorpyrifos, rather than its active
metabolite, chlorpyrifos oxon, is the primary
agent in these effects.
Our findings also extend the results to
another organophosphate, diazinon, suggest-
ing that chlorpyrifos is not unique in its
adverse effects on neural cell replication.
Like chlorpyrifos, diazinon showed immedi-
ate onset of effects and preferential actions
on gliotypic cells. Similarly, diazinon has
been shown to disrupt neurodevelopment in
aquatic species (45,46) and elicits dysmor-
phogenesis in sea urchins during the phase
in which neurotrophic factors control devel-
opment (47). The effects, however, are not
shared by non-organophosphate pesticides:
We previously found dieldrin to be ineffec-
tive in the sea urchin model (37), and
physostigmine, a carbamate, was much less
effective, as found here. The smaller effect of
physostigmine is nevertheless of some addi-
tional interest, especially because inhibition
was seen only in C6 cells and not in the neu-
ronotypic cells. Given the greater effect of
chlorpyrifos compared to chlorpyrifos oxon,
it is highly unlikely that inhibition of
cholinesterase per se is responsible for the
effect of physostigmine, and it certainly
could not explain differential sensitivity of
the two cell lines. Cholinesterase plays a
nonenzymatic role in the proliferation of
glial cells (48,49), and it is possible that
physostigmine affects structural aspects of
the cholinesterase molecule in a manner dif-
ferent from that of chlorpyrifos or chlorpyri-
fos oxon; further study will be needed to
characterize any such effect. Physostigmine
also can interact directly with nicotinic
cholinergic receptors (50), but one would
then expect PC12 cells, which are enriched
in these receptors, to be targeted far more
than C6 cells, which are not, rather than the
converse, as found here.
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Figure 3. Effects of standard serum conditions on
the ability of chlorpyrifos (CPF; 15 µM) to inhibit
DNA synthesis in PC12 and C6 cells. PC12 cells
were grown in the presence of 10% horse serum +
5% fetal bovine serum; C6 cells were grown with
5% fetal bovine serum. Serum was then deleted
(no serum) or continued (with serum) during the
chlorpyrifos exposure period. Data represent
means and SEs obtained from 9–11 determinations
for each treatment and cell type, presented as the
percentage of corresponding control values:
13,600 ± 120 dpm/µg DNA for PC12 cells without
serum, 10,700 ± 150 with serum (p < 0.0001); 6,600 ±
100 for C6 cells without serum, 8,200 ± 300 with
serum (p < 0.0002). DNA content was 27 ± 1
µg/dish for PC12 cells and 33 ± 1 for C6 cells, and
was unaffected by the addition of serum or by the
chlorpyrifos treatment (data not shown). ANOVA:
treatment, p < 0.0001; treatment × cell type, p <
0.0001; treatment ×  serum, p < 0.0001; treatment ×
cell type ×  serum, p < 0.0001. Treatment with
chlorpyrifos elicited signiﬁcant reductions in DNA
synthesis (a) in both cell types in the absence of
serum; the effect was greater on C6 than on PC12
cells (b). The addition of serum prevented most of
the effect of chlorpyrifos on PC12 cells (c) but did
not protect C6 cells.
Figure 4. Effects of different serum mixtures on
the ability of chlorpyrifos (15 µM) to inhibit DNA
synthesis in C6 cells. C6 cells were grown with
5% fetal bovine serum (FBS) and then serum was
either deleted or continued (no serum) during the
chlorpyrifos exposure period, or a different serum
mixture used for PC12 cells was added [10%
horse serum (HS) + 5% FBS], or bovine serum
albumin (BSA) was added to achieve the same
protein concentration as in the PC12 serum mix-
ture. Data represent means and standard errors
obtained from 5–20 determinations for each com-
bination of treatment and serum condition, pre-
sented as the percentage of corresponding
control values (see legend to Figure 3). ANOVA:
treatment, p < 0.0001; treatment × serum, p <
0.0001. Treatment with chlorpyrifos elicited signif-
icant reductions in DNA synthesis (a) in the pres-
ence or absence of 5% FBS. Addition of 10% HS +
5% FBS protected the cells from chlorpyrifos (b)
and a similar protection was obtained with BSA.
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a,cA major limitation of the current study is
the use of transformed cell lines, which pro-
vide the advantage of a uniform cell popula-
tion undergoing synchronous replication,
but which are less responsive to neurotoxins
such as chlorpyrifos (1,6,8,11,17,18,21,22).
Accordingly, whereas potencies of different
chemicals can be compared in these systems,
it is difficult to relate the absolute levels
required for these actions to safety thresholds
in vivo. Given the requirement that serum
proteins be excluded from the medium for
comparisons of PC12 and C6 cells (dis-
cussed below), the determinations here also
are limited to short-term studies, because the
prolonged absence of sera terminates cell
division, initiates differentiation into several
phenotypes, and eventually can elicit apop-
tosis (11,34–36). When studies are con-
ducted over a much longer time frame,
considerably lower concentrations of chlor-
pyrifos evoke inhibition of DNA synthesis
and other neurotoxic events culminating in
cell damage and loss (1,11,18).
Despite these constraints, in vitro sys-
tems allow for the dissection of speciﬁc cellu-
lar mechanisms underlying developmental
neurotoxicity, in this case the direct inhibi-
tion of DNA synthesis as a separable event
from cholinesterase inhibition. Furthermore,
these results can be combined with in vivo
data to give insight into unexpected conse-
quences. Thus, combined with pharmacoki-
netic information (51), our finding of a
slight inhibitory activity of TCP on DNA
synthesis assumes greater importance. TCP
accumulates in high concentrations in fetal
brain after maternal chlorpyrifos administra-
tion (51) and is also the major chlorpyrifos
residue in children (25,26); the smaller in
vitro effect of TCP than chlorpyrifos found
here may thus represent a much more
important effect in vivo. On the other hand,
the fact that chlorpyrifos oxon was more
potent than TCP and less potent than chlor-
pyrifos probably indicates that the oxon does
not contribute signiﬁcantly to mitotic inhi-
bition and loss of cells in vivo, in light of the
much lower concentrations and short bio-
logic half-life of this active metabolite (51).
Unlike chlorpyrifos, TCP did not show a
preferential effect toward gliotypic cells,
implying that this supposedly inactive
metabolite (52) may in fact have a more
ubiquitous effect on neural cell develop-
ment, targeting neurons and glia equally.
Indeed, TCP, like chlorpyrifos, has been
shown to inhibit neurite outgrowth in
neuronotypic PC12 cells (11). Accordingly,
future studies should examine the potential
developmental neurotoxicity of TCP.
Finally, our results address the important
issue of differential neurotoxicity of chlor-
pyrifos in the developing brain compared to
the mature brain. Previous work with PC12
cells suggested that horse serum, although
heat-inactivated, nevertheless might main-
tain sufﬁcient A esterase and carboxylesterase
activity to hydrolyze chlorpyrifos oxon and
thus provide protection from its adverse
effects (11). Although the ability of these
enzymes to hydrolyze chlorpyrifos is poorly
characterized, we were indeed able to show
that addition of inactivated horse serum to
the medium protected PC12 cells from the
inhibition of DNA synthesis evoked by
chlorpyrifos. Furthermore, although horse
serum is not ordinarily required to maintain
growth of C6 cells, the combination of 10%
horse serum and 5% fetal bovine serum was
able to protect these cells from chlorpyrifos
as well; the lower concentrations of fetal
bovine serum alone, typically used with C6
cells, did not protect the cells from chlor-
pyrifos. Surprisingly, though, we found
equivalent protection when we added albu-
min to achieve the same total protein con-
centration as provided by the sera. This
implies that the protective effect is not an
artifact of residual enzymatic activity after
heat inactivation but most likely represents
binding of chlorpyrifos to serum protein.
The fact that serum proteins can bind
chlorpyrifos and thus protect developing
neural cells may be of key importance for
fetal and neonatal neurotoxicity, because
their plasma protein binding is deficient
relative to the adult (53). Thus, at the same
plasma concentration of chlorpyrifos, a
greater proportion of the compound will be
biologically active in the immature organ-
ism. Accordingly, the development of bind-
ing proteins may prove to be as important
for organophosphate-induced developmen-
tal neurotoxicity as serum esterase activity
(54–57).
In conclusion, chlorpyrifos and other
organophosphates such as diazinon have
immediate, direct inhibitory actions on
DNA synthesis and hence on neural cell
replication, with preferential targeting of
gliotypic cells. The active metabolite, chlor-
pyrifos oxon, is less effective than chlorpyri-
fos, indicating that the antimitotic effects are
separable from inhibition of cholinesterase.
However, additional effects may be con-
tributed by the supposedly inactive major
metabolite, TCP. In light of the protective
effect of serum-binding proteins, the fact
that the fetus and newborn possess lower
concentrations of these proteins suggests that
greater neurotoxic effects can occur at the
same blood levels of chlorpyrifos that are
nontoxic to adults. In vitro cultures of neural
cells can thus permit the determination of
the mechanisms underlying developmental
neurotoxicity of pesticides, as well as provid-
ing a rapid screening procedure.
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